BMEA - Biomea Fusion, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Redwood City,
United States
Type: Equity
BMEA price evolution
BMEA
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $93.6 | $116.29 | $147.57 | $179.18 |
| Long term investments | ||||
| Property, plant & equipment | $11.82 | $12.76 | $13.82 | $14.87 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $110.42 | $136.16 | $168.49 | $199.93 |
| Current liabilities | ||||
| Accounts payable | $8.99 | $5.83 | $4.71 | $6.85 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $27.57 | $25.16 | $25.25 | $22.86 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $34.45 | $32.22 | $33.18 | $30.69 |
| Shareholders' equity | ||||
| Retained earnings | -$357.95 | -$325.16 | -$287.89 | -$248.82 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $179.18 | $117.82 | $176.56 | $62.22 |
| Long term investments | ||||
| Property, plant & equipment | $14.87 | $7.99 | $5.69 | $0.29 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $199.93 | $129.31 | $185.71 | $62.53 |
| Current liabilities | ||||
| Accounts payable | $6.85 | $6.83 | $1.33 | $0.73 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $22.86 | $19.1 | $4.64 | $1.62 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $30.69 | $20.77 | $6.92 | $1.62 |
| Shareholders' equity | ||||
| Retained earnings | -$248.82 | -$131.57 | -$49.74 | -$8.18 |
| Other shareholder equity | -$0 | -$0.01 | ||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $34.04 | $38.9 | $41.06 | $37.33 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $1.25 | $1.62 | $2 | $2.44 |
| Net income | ||||
| Net income | -$32.79 | -$37.28 | -$39.06 | -$34.88 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $126.14 | $83.63 | $5.33 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $8.88 | $1.81 | ||
| Net income | ||||
| Net income | -$117.25 | -$81.83 | -$5.32 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.28 | -$0.09 | -$0.04 | -$2.22 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $1.25 | $1.19 | $0.12 | $163.8 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$88.92 | -$63.58 | -$31.95 | $64.99 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$2.22 | $27.34 | -$33.35 | -$0.05 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $163.8 | $1.24 | $153.19 | $65.97 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $64.99 | -$33.84 | $84.4 | $61.46 |
News
Fundamentals
| Market cap | $48.20M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 36.24M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$144.01M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.33 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$3.97 |
|---|---|
| ROA | -93.66% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.39 |
| Quick ratio | N/A |